India, Oct. 23 -- Glenmark Pharmaceuticals Inc., USA, has announced the upcoming launch of Ropivacaine Hydrochloride Injection USP in three strengths — 40 mg/20 mL (2 mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) single-dose vials.
The product is bioequivalent and therapeutically equivalent to the reference listed drug Naropin® Injection by Fresenius Kabi USA, LLC. Distribution is set to begin in November 2025.
According to IQVIA® data for the 12 months ending August 2025, the Naropin® market achieved annual sales of approximately $20.9 million.
Marc Kikuchi, President and Business Head – North America, said, "This launch marks another significant addition to Glenmark's expanding injectable portfolio...